As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Exelixis, Inc. The largest reported stake is Farallon Capital Management, L.L.C.'s, at 6%. 8 filings are on record since January 5, 2026 (Schedule 13G, November 9, 2026).
Sell to companies like Exelixis, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Farallon Capital Management, L.L.C. · Percent: 6% · Shares: 14,694,910 · SCHEDULE 13G
- · Holder: Farallon Capital Management, L.L.C. · Percent: 4.9% · SCHEDULE 13D/A
- · Holder: Farallon Capital Management, L.L.C. · Percent: 5.6% · SCHEDULE 13D/A
- · Reporting person: AQR Capital Management, LLC · Sole voting: 0 · Shared voting: 10,935,221 · Sole dispositive: 0 · Shared dispositive: 11,023,943 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: Vanguard Capital Management · Sole voting: 1,974,263 · Shared voting: 0 · Sole dispositive: 13,233,247 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-29
Exelixis, Inc. has 8 Schedule 13D or 13G filings on record since 2026-01-05. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share (the "shares"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 6% | 14,694,910 | SCHEDULE 13G, 2026-11-09 | 2026-11-09 |
| Farallon Capital Partners, L.P. | 5.9% | 1,189,334 | SCHEDULE 13D/A, 2026-01-05 | 2026-01-01 |
| Vanguard Capital Management | 5.09% | 13,233,247 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| AQR Capital Management, LLC | 4.39% | 11,023,943 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Exelixis, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Exelixis, Inc. and the records around it.
Exelixis, Inc. elsewhere on the record
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026), Savara Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Watch Exelixis, Inc.
Get an email when Exelixis, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Exelixis, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Exelixis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Exelixis, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Dapice Joshua J. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Dreyfuss, Philip D. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Dunn Hannah E. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Gehani, Varun N. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Giauque, Nicolas | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Husen, Avner A. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Kim, David T. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Linn, Michael G. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Luo Patrick (Cheng) | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Roberts, Jr., Thomas G. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Saito Edric C. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Short Daniel S. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Spokes, Andrew J. M. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Warren, John R. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Wehrly, Mark C. | 0 | 14,694,910 | 0 | 14,694,910 | SCHEDULE 13G, 2026-11-09 |
| Vanguard Capital Management | 1,974,263 | 0 | 13,233,247 | 0 | SCHEDULE 13G, 2026-04-29 |
| AQR Capital Management, LLC | 0 | 10,935,221 | 0 | 11,023,943 | SCHEDULE 13G/A, 2026-08-12 |
| AQR Capital Management Holdings, LLC | 0 | 10,935,221 | 0 | 11,023,943 | SCHEDULE 13G/A, 2026-08-12 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
The latest filing identifies Exelixis, Inc. by CUSIP 30161Q104 and gives its principal executive office as 1851 Harbor Bay Parkway, Alameda, CA 94502 (SCHEDULE 13G, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-05 | Farallon Capital Partners, L.P. | 5.9% | SCHEDULE 13D/A |
| 2026-02-13 | AQR Capital Management, LLC | 5.09% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Capital Management | 5.09% | SCHEDULE 13G |
| 2026-08-12 | AQR Capital Management, LLC | 4.39% | SCHEDULE 13G/A |
| 2026-08-14 | Farallon Capital Management, L.L.C. | 5.6% | SCHEDULE 13D/A |
| 2026-11-09 | Farallon Capital Management, L.L.C. | 4.9% | SCHEDULE 13D/A |
| 2026-11-09 | Farallon Capital Management, L.L.C. | 6% | SCHEDULE 13G |
Questions about who owns Exelixis, Inc.
Who owns Exelixis, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Exelixis, Inc.: Farallon Capital Management, L.L.C. (6%, Schedule 13G, filed 2026-11-09), Farallon Capital Partners, L.P. (5.9%, Schedule 13D/A, filed 2026-01-05) and Vanguard Capital Management (5.09%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Exelixis, Inc.?
By the share each holder's latest filing reports, the largest holders of Exelixis, Inc. on this page are Farallon Capital Management, L.L.C. (6%), Farallon Capital Partners, L.P. (5.9%) and Vanguard Capital Management (5.09%).
When did Farallon Capital Management, L.L.C. buy into Exelixis, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Farallon Capital Management, L.L.C. on this page is the Schedule 13D/A, filed 2026-08-14, reporting 5.6%; its latest, Schedule 13G filed 2026-11-09, reports 6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Exelixis, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.